Herman 1979.

Study characteristics
Methods	Randomised, double‐blinded, 2‐period cross‐over study
Participants	152 people (126 men/26 women) aged 15‐74 years (median = 33 years) Tumour type: testicular carcinoma (70 people), non‐Hodgkin's disease (12 people), Hodgkin's disease (11 people) Chemotherapy regimen: cisplatin daily for 5 days, vinblastine and bleomycin (70 people); cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP 12 people); nitrogen mustard (mechlorethamine?), vincristine, procarbazine and prednisone (MOPP 11 people); other regimens included dactinomycin, dacarbazine, 5‐fluorouracil, melphalan and nitrosourea compounds. No information on doses reported Chemotherapy emetogenicity: high
Interventions	Nabilone 2 mg, every 8 hours orally, n = 152 Prochlorperazine 10 mg, every 8 hours orally, n = 152
Outcomes	Episodes of nausea and vomiting daily during chemotherapy; withdrawal due to adverse effects; episodes of somnolence, dizziness, depression, euphoria, preference
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Low risk	"Drugs packaged in identical containers marked only with a number code"
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	113/152 (74%) participants received nabilone, 113/152 (74%) participants received prochlorperazine
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	Unclear risk	Assumed washout period sufficient. Unclear if paired analysis was performed. Unclear if groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Identical containers marked only with a number code"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double‐blind" and "identical containers marked only with a number code"